Literature DB >> 8215019

Expression of insulin-like growth factor-I in transgenic mice.

A J D'Ercole1.   

Abstract

The studies reviewed above provide strong evidence for the concept that IGF-I plays an essential role in mediating the growth-promoting actions of GH, and thus, they support the central elements of the "somatomedin hypothesis." The data, however, also point to actions of each GH and IGF-I that are not linked. Many hormones and factors, other than GH, are known to regulate the expression of IGF-I, as well as its binding proteins (modulators of its actions), in a tissue-specific fashion. Some of these influences, e.g., estrogens, thyroid hormone, and nutritional factors, also effect GH synthesis and/or secretion. This complex and precise regulation undoubtedly plays a key role in coordinating the somatic and visceral growth stimulated by GH and IGF-I. The evidence that GH and IGF-I actions are not always coupled, therefore, is not surprising. The challenge is to dissect the precise role(s) of GH and IGF-I, as well as other hormones and growth factors, in the control of growth. Study of transgenic animals provides a powerful way to approach these issues in vivo. These studies demonstrate that IGF-I is capable of stimulating in vivo brain growth. The transgene IGF-I-stimulated increase in brain size appears to result both from an increase in cell number and, as demonstrated by Carson et al., from an increase in myelin content, which in turn may result from proliferation of oligodendrocytes. Other roles for IGF-I in brain growth and development, however, are possible and amply supported by numerous studies of brain-derived cultured cells (see other papers herein). Because IGF-I is normally expressed in brain, it seems reasonable to assume that the IGF-I-stimulated brain growth observed in these transgenic mice represents a response to IGF-I overexpression rather than a pharmacologic response that is not indicative of a normal IGF-I function. Study of this IGF-I transgenic line cannot address the developmental period(s) when IGF-I normally stimulates brain growth, but this transgenic line provides a model to investigate IGF-I's specific role and its mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215019     DOI: 10.1111/j.1749-6632.1993.tb26213.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 2.  The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system.

Authors:  F Folli; S Ghidella; L Bonfanti; C R Kahn; A Merighi
Journal:  Mol Neurobiol       Date:  1996-10       Impact factor: 5.590

Review 3.  Organ-Size Regulation in Mammals.

Authors:  Alfredo I Penzo-Méndez; Ben Z Stanger
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-07-17       Impact factor: 10.005

4.  Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice.

Authors:  J Wang; W Niu; Y Nikiforov; S Naito; S Chernausek; D Witte; D LeRoith; A Strauch; J A Fagin
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 5.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

Review 6.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

7.  Actions and interactions of growth hormone and insulin-like growth factor-II: body and organ growth of transgenic mice.

Authors:  A Blackburn; A Schmitt; P Schmidt; R Wanke; W Hermanns; G Brem; E Wolf
Journal:  Transgenic Res       Date:  1997-05       Impact factor: 2.788

Review 8.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

Review 9.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

10.  Differential inhibition of postnatal brain, spinal cord and body growth by a growth hormone antagonist.

Authors:  D L McIlwain; V B Hoke; J J Kopchick; C R Fuller; P K Lund
Journal:  BMC Neurosci       Date:  2004-02-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.